Trial Profile
A study investigating intrathecal antibody responses during of Natalizumab treatment associated with natalizumab-associated progressive multifocal leukoencephalopathy (PML) and progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome (PML-IRIS) in patients with multiple sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 27 Feb 2016 New trial record